Ajanta Pharma share price
You have to be logged in to add this to Watchlist.- ₹2,777.00(2.84%)July 16, 2025 15:29:46 PM IST
- NSE
- BSE
- Vol : 301.02K (NSE + BSE)Last 20 day avg : 164.23 K
Ajanta Pharma is trading 2.84% upper at Rs 2,777.00 as compared to its last closing price. Ajanta Pharma has been trading in the price range of 2,796.80 & 2,690.00. Ajanta Pharma has given -8.00% in this year & 3.34% in the last 5 days. Ajanta Pharma has TTM P/E ratio 35.71 as compared to the sector P/E of 23.03.There are 10 analysts who have initiated coverage on Ajanta Pharma. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 225.26 Crores in its last quarter.Listed peers of Ajanta Pharma include Suven Pharmaceuticals (0.58%), Ipca Laboratories (-0.52%), Ajanta Pharma (2.84%).The Mutual Fund holding in Ajanta Pharma was at 15.13% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Ajanta Pharma was at 8.86% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 16, 2025, 03:22 PM UTC
- Dividend YieldInline with the industry1.04Annual dividends as a percentage of the stock price.
- P/BHigher than historical values8.88The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values36.72Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.43Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.01The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 11.04% from Rs 1170.41 crore to Rs 1054.08 crore, year-on-year
- The company has grown its March quarter profit by 11.12% from Rs 202.72 crore to Rs 225.26 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,695.13
- R2
- 2,816.77
- R3
- 2,917.38
- S1
- 2,472.88
- S2
- 2,372.27
- S3
- 2,250.63
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Suven Pharmaceuticals | Neutral | 1,061.50 | 0.58 | 40,229.96 | 96.40 | 15.12 | - | 10.36 |
| Ipca Laboratories | Moderately Bullish | 1,462.65 | -0.52 | 37,014.63 | 40.79 | 5.17 | 0.28 | 8.55 |
| Ajanta Pharma | Moderately Bullish | 2,777.00 | 2.84 | 34,645.86 | 35.77 | 8.67 | 2.05 | 0.92 |
| Gland Pharma | Bullish | 1,970.75 | 3.94 | 32,529.99 | 44.21 | 3.37 | 0.96 | 1.17 |
| Wockhardt | Bullish | 1,820.30 | -0.50 | 29,666.74 | - | 6.51 | - | 30.00 |
Pledged found - Promoter(s) have pledged 12.61% of shares.- Promoter(s) have increased pledged shares to 11.17% from 12.61% earlier.
- Promoter(s) holds a high stake in the company at 66.26%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.40 percentage points from previous quarter
- Mutual Funds holding has increased by 0.24 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-04-30 | Audited Results & A.G.M. |
| 2025-01-30 | Quarterly Results |
| 2024-10-28 | Quarterly Results |
| 2024-07-30 | Quarterly Results |
| 2024-05-02 | Audited Results & Buy Back of Shares |
- IndustryBiotechnology & Drugs
- ISININE031B01049
- BSE Code532331
- NSE CodeAJANTPHARM
Ajanta Pharma is trading at 2777.00 as on Wed Jul 16 2025 09:59:46. This is 2.84% upper as compared to its previous closing price of 2700.40.
The market capitalization of Ajanta Pharma is 34645.86 Cr as on Wed Jul 16 2025 09:59:46.
The 52 wk high for Ajanta Pharma is 3485.75 whereas the 52 wk low is 2022.05
Ajanta Pharma can be analyzed on the following key metrics -
- TTM P/E: 35.71
- Sector P/E: 23.03
- Dividend Yield: 1.04%
- D/E ratio: 0.01
Ajanta Pharma reported a net profit of 920.39 Cr in 2025.
The Mutual Fund Shareholding was 15.13% at the end of 31 Mar 2025.